Xarah Fe NDC 70700-310

NDC codes

FDA NDC Directory

Product NDC (as listed)70700-310Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70700-0310Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70700-310-85	70700031085	3 POUCH in 1 CARTON (70700-310-85) / 1 BLISTER PACK in 1 POUCH (70700-310-84) / 1 KIT in 1 BLISTER PACKMarketed from Jan 29, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Xarah Fe
Generic name (nonproprietary): norethindrone acetate and ethinyl estradiol and ferrous fumarate tablets
Dosage form: Kit
Labeler: Xiromed LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 205069
Marketing start: Jan 29, 2025
Listing expires: Dec 31, 2026
Identifiers: Product ID 70700-310_817ee8b8-f24d-0dfd-e969-2f5ef8d8cbb8SPL ID 817ee8b8-f24d-0dfd-e969-2f5ef8d8cbb8SPL set ID 2c5cf9c3-948e-964b-7424-21c84461df93RxCUI 259176, 1358762, 1359130, 1359131, 1359132, 2703554

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N470700031085 followed by a unit qualifier and the quantity

Package 70700-0310-85. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 5, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Xarah Fe is indicated for the prevention of pregnancy in women who elect to use combined oral contraceptives as a method of contraception. Xarah Fe is indicated for the treatment of moderate acne vulgaris in females, ≥ 15 years of age, who have no known contraindications to combined oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. Xarah Fe should be used for the treatment of acne only if the patient desires a combined oral contraceptive for birth control and plans to stay on it for at least 6 months. Combined oral contraceptives are highly effective for pregnancy prevention. Table 2 lis…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 205069

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 205069
Product	Strength	Form · route	Labeler	Product NDC
Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate	—	Kit	Mylan Pharmaceuticals Inc.	0378-7303